DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

Add to watchlist

$1.87 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 85 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 43.6% .

All

			Value		Shares		↓ Weighting
HZNP	Sell	HORIZON PHARMA PLC	$106,811,000	-34.0%	8,998,413	-17.8%	5.70%	-8.7%
GILD	Sell	GILEAD SCIENCES INC	$66,428,000	-18.7%	938,515	-22.0%	3.54%	+12.4%
	Sell	HORIZON PHARMA INVT LTDnote 2.500% 3/1	$64,002,000	-23.2%	74,100,000	-17.8%	3.41%	+6.3%
MYL	Sell	MYLAN N V	$53,072,000	-33.3%	1,367,119	-33.1%	2.83%	-7.8%
	Sell	ISIS PHARMACEUTICALS INC DELnote 1.000%11/1	$44,891,000	-25.5%	42,200,000	-32.5%	2.39%	+3.1%
AVDL	Sell	AVADEL PHARMACEUTICALS PLCsponsored adr	$40,320,000	+2.3%	3,655,494	-10.2%	2.15%	+41.4%
GWPH	Sell	GW PHARMACEUTICALS PLCads	$36,088,000	-29.9%	359,983	-15.4%	1.92%	-3.0%
LCI	Sell	LANNET INC	$31,089,000	-25.0%	1,523,957	-17.8%	1.66%	+3.8%
NVRO	Sell	NEVRO CORP	$28,009,000	-25.8%	376,308	-6.6%	1.49%	+2.6%
DBVT	Sell	DBV TECHNOLOGIES S Asponsored adr	$23,754,000	-61.3%	665,197	-61.8%	1.27%	-46.5%
PTLA	Sell	PORTOLA PHARMACEUTICALS INC	$23,535,000	-58.6%	419,000	-71.1%	1.26%	-42.8%
	Sell	INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0	$21,983,000	-44.4%	22,500,000	-47.1%	1.17%	-23.1%
SYRS	Sell	SYROS PHARMACEUTICALS INC	$20,417,000	-20.6%	1,268,945	-21.4%	1.09%	+9.8%
LOXO	Sell	LOXO ONCOLOGY INC	$20,141,000	-36.5%	251,167	-66.7%	1.07%	-12.2%
AET	Sell	AETNA INC NEW	$19,738,000	-42.0%	130,000	-51.3%	1.05%	-19.8%
AAAP	Sell	ADVANCED ACCELERATOR APPLICsponsored ads	$15,339,000	-26.4%	392,904	-24.9%	0.82%	+1.7%
GLPG	Sell	GALAPAGOS NVspon adr	$14,348,000	-35.9%	187,501	-27.8%	0.76%	-11.4%
ANTM	Sell	ANTHEM INC	$14,144,000	-73.1%	75,182	-76.4%	0.75%	-62.8%
REPH	Sell	RECRO PHARMA INC	$13,369,000	-26.3%	1,901,685	-8.4%	0.71%	+2.0%
ANAB	Sell	ANAPTYSBIO INC	$13,230,000	-43.6%	552,859	-34.6%	0.71%	-22.0%
EHTH	Sell	EHEALTH INC	$12,979,000	-59.2%	690,348	-73.9%	0.69%	-43.6%
XNCR	Sell	XENCOR INC	$11,869,000	-61.4%	562,236	-56.2%	0.63%	-46.6%
CTMX	Sell	CYTOMX THERAPEUTICS INC	$11,731,000	-28.0%	756,822	-19.8%	0.63%	-0.3%
ASND	Sell	ASCENDIS PHARMA A Ssponsored adr	$11,644,000	-55.2%	419,453	-54.9%	0.62%	-38.1%
AXGN	Sell	AXOGEN INC	$11,297,000	-41.2%	674,428	-63.3%	0.60%	-18.6%
NEOS	Sell	NEOS THERAPEUTICS INC	$10,652,000	-29.5%	1,459,195	-30.5%	0.57%	-2.6%
BPMC	Sell	BLUEPRINT MEDICINES CORP	$10,286,000	-81.2%	203,000	-85.1%	0.55%	-73.9%
EPZM	Sell	EPIZYME INC	$10,002,000	-58.7%	662,369	-53.1%	0.53%	-42.9%
CNC	Sell	CENTENE CORP DEL	$9,506,000	-77.9%	119,000	-80.3%	0.51%	-69.4%
STDY	Sell	STEADYMED LTD	$9,084,000	-10.8%	1,441,913	-17.9%	0.48%	+23.4%
IVTY	Sell	INVUITY INC	$8,535,000	-36.5%	1,177,229	-30.4%	0.46%	-12.2%
ALIM	Sell	ALIMERA SCIENCES INC	$6,630,000	-19.4%	4,769,551	-18.9%	0.35%	+11.7%
AXGT	Sell	AXOVANT SCIENCES LTD	$5,547,000	-34.6%	239,180	-57.9%	0.30%	-9.5%
MYOV	Sell	MYOVANT SCIENCES LTD	$4,688,000	-43.4%	400,685	-43.2%	0.25%	-21.6%
SRRA	Sell	SIERRA ONCOLOGY INC	$4,090,000	-46.2%	3,495,734	-29.7%	0.22%	-25.6%
AKTX	Sell	AKARI THERAPEUTICS PLCsponsored adr	$3,772,000	-70.4%	818,158	-28.9%	0.20%	-59.1%
MYOK	Sell	MYOKARDIA INC	$3,665,000	-34.4%	279,752	-34.1%	0.20%	-9.3%
BIOS	Sell	BIOSCRIP INC	$3,605,000	+7.6%	1,327,966	-32.6%	0.19%	+48.8%
AGRX	Sell	AGILE THERAPEUTICS INC	$3,582,000	+15.0%	955,109	-1.7%	0.19%	+59.2%
JNCE	Sell	JOUNCE THERAPEUTICS INC	$3,478,000	-66.3%	247,872	-47.1%	0.19%	-53.3%
KMPH	Sell	KEMPHARM INC	$2,818,000	-47.0%	704,612	-35.0%	0.15%	-26.8%
PRTO	Sell	PROTEON THERAPEUTICS INC	$1,868,000	-19.9%	1,224,899	-8.1%	0.10%	+11.1%
RARX	Sell	RA PHARMACEUTICALS INC	$1,548,000	-59.1%	82,593	-53.6%	0.08%	-43.2%
	Sell	ESSA PHARMA INC	$779,000	-88.2%	1,416,230	-33.2%	0.04%	-83.5%
SNDX	Exit	SYNDAX PHARMACEUTICALS INC	$0	–	-38,130	-100.0%	-0.02%	–
STRM	Exit	STREAMLINE HEALTH SOLUTIONS	$0	–	-662,971	-100.0%	-0.03%	–
CRVS	Exit	CORVUS PHARMACEUTICALS INC	$0	–	-36,931	-100.0%	-0.03%	–
THLD	Exit	THRESHOLD PHARMACEUTICAL INC	$0	–	-2,202,160	-100.0%	-0.05%	–
TVTY	Exit	TIVITY HEALTH INC	$0	–	-76,000	-100.0%	-0.08%	–
PSDV	Exit	PSIVIDA CORP	$0	–	-1,492,824	-100.0%	-0.10%	–
CASM	Exit	CAS MED SYS INC	$0	–	-1,798,434	-100.0%	-0.10%	–
ADPTQ	Exit	ADEPTUS HEALTH INCcl a	$0	–	-1,600,861	-100.0%	-0.11%	–
SCYX	Exit	SCYNEXIS INC	$0	–	-1,048,000	-100.0%	-0.11%	–
GNCA	Exit	GENOCEA BIOSCIENCES INC	$0	–	-479,000	-100.0%	-0.11%	–
	Exit	ACORDA THERAPEUTICS INCnote 1.750% 6/1	$0	–	-5,000,000	-100.0%	-0.16%	–
FPRX	Exit	FIVE PRIME THERAPEUTICS INC	$0	–	-138,000	-100.0%	-0.19%	–
KITE	Exit	KITE PHARMA INC	$0	–	-81,000	-100.0%	-0.24%	–
INFI	Exit	INFINITY PHARMACEUTICALS INC	$0	–	-1,969,225	-100.0%	-0.24%	–
NSTG	Exit	NANOSTRING TECHNOLOGIES INC	$0	–	-352,375	-100.0%	-0.27%	–
TGTX	Exit	TG THERAPEUTICS INC	$0	–	-700,000	-100.0%	-0.32%	–
SAGE	Exit	SAGE THERAPEUTICS INC	$0	–	-122,000	-100.0%	-0.33%	–
GMED	Exit	GLOBUS MED INCcl a	$0	–	-308,000	-100.0%	-0.35%	–
BLUE	Exit	BLUEBIRD BIO INC	$0	–	-107,064	-100.0%	-0.38%	–
TSRO	Exit	TESARO INC	$0	–	-66,000	-100.0%	-0.39%	–
ARRY	Exit	ARRAY BIOPHARMA INC	$0	–	-1,142,744	-100.0%	-0.39%	–
	Exit	IMPAX LABORATORIES INCnote 2.000% 6/1	$0	–	-17,000,000	-100.0%	-0.54%	–
HUM	Exit	HUMANA INC	$0	–	-69,185	-100.0%	-0.55%	–
ONCE	Exit	SPARK THERAPEUTICS INC	$0	–	-283,000	-100.0%	-0.58%	–
VRX	Exit	VALEANT PHARMACEUTICALS INTL	$0	–	-1,500,000	-100.0%	-0.64%	–
MYL	Exit	MYLAN N Vcall	$0	–	-450,000	-100.0%	-0.68%	–
	Exit	HEALTHWAYS INCnote 1.500% 7/0	$0	–	-11,600,000	-100.0%	-0.69%	–
	Exit	WRIGHT MED GROUP INCnote 2.000% 2/1	$0	–	-20,025,000	-100.0%	-0.92%	–
UAM	Exit	UNIVERSAL AMERN CORP NEW	$0	–	-2,833,531	-100.0%	-1.09%	–
WBA	Exit	WALGREENS BOOTS ALLIANCE INC	$0	–	-355,957	-100.0%	-1.14%	–
	Exit	ARRAY BIOPHARMA INCnote 3.000% 6/0	$0	–	-22,385,000	-100.0%	-1.23%	–
VNDA	Exit	VANDA PHARMACEUTICALS INC	$0	–	-2,299,046	-100.0%	-1.24%	–
	Exit	MOLINA HEALTHCARE INCdbcv 1.625% 8/1	$0	–	-35,000,000	-100.0%	-1.43%	–
	Exit	ENDOLOGIX INCnote 2.250%12/1	$0	–	-51,117,000	-100.0%	-1.90%	–

Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Flynn Management LLC #1

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2017-08-14

Signatures

The EDGAR filing(s) were signed by:

Flynn Management LLC, its general partner and James E. Flynn — Managing Member

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
AERIE PHARMACEUTICALS INC	36	Q3 2022	3.6%
CENTENE CORP DEL	30	Q3 2023	3.0%
BIOCRYST PHARMACEUTICALS INC	29	Q3 2023	2.2%
MOLINA HEALTHCARE INC	26	Q3 2022	1.7%
EHEALTH INC	25	Q3 2020	2.0%
INTERCEPT PHARMACEUTICALS IN	24	Q1 2023	2.2%
MYLAN NV	23	Q3 2020	6.2%
PORTOLA PHARMACEUTICALS INC	23	Q1 2019	6.0%
BROOKDALE SR LIVING INC	23	Q3 2023	2.2%
ALIMERA SCIENCES INC	23	Q3 2019	0.8%

View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.

Latest significant ownerships (13-D/G)

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Q2 2017 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
DA32 Life Science Tech Acquisition Corp.	August 01, 2023	5,145,000	91.1%
CareMax, Inc.	March 13, 2023	18,691,423	16.4%
CareMax, Inc.	June 02, 2022	18,691,423	20.7%

View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.

Latest filings

Type	Filed
13F-HR	2024-05-15
3	2024-03-19
4	2024-03-19
4	2024-03-12
3	2024-03-08
4	2024-02-16
13F-HR	2024-02-14
4	2024-02-08
3	2024-02-01
4	2023-11-21

View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.

All filings

View complete filings history.

Compare quarters

Export DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s holdings

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) - Q2 2017 holdings